Research Progress of LncRNA and Other Epigenetics in Triple-negative Breast Cancer

Abstract

For lacking of HR and HER-2, triple-negative breast cancer (TNBC) is one type of breast cancers with the worst prognosis. The current treatments are mainly chemotherapy, radiotherapy and surgery, but the results are still not satisfactory, which leads us to explore the new molecular markers or new therapeutic targets.. LncRNA and its related epigenetic modifications may provide new targets for the treatment of TNBC. This paper reviews the existing studies on LncRNA and other epigenetic changes as TNBC biomarkers and their potential use as TNBC therapeutic targets.

Keywords

• lncrna
• triple-negative breast cancer
• dna methylation
• epigenetics